Выбор редакции

BofA lifts target on AbbVie

  • "We continue to assume solid annual sales growth for Humira (albeit at a slowing rate) until 2017 when we begin to build in modest shrinkage due to increased competition, biosimilar or otherwise,” BofA's Gregg Gilbert says, reiterating a Buy rating on shares of AbbVie (ABBV -0.6%).
  • Price target is lifted to $56 from $53 apparently to reflect potential in HCV.
  • More on generic Humira
  • More on the HCV pipeline
Post your comment!